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Introduction 
 
iabetes Mellitus (DM) is epidemic 
worldwide and it is estimated to affect  
366 million by 2030 when majority of those 
affected will be living in low and middle 
income countries where Mycobacterium 
Tuberculous infection is endemic 1,2. The 
combination of DM and tuberculosis (TB) 
was life threatening in the pre-antibiotic era 
and before the readily available treatment of 
both diseases 3. Currently the association  
D
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Abstract 
Objective 
To provide an overview, understanding and future prediction of the prevalent concomitant 
diabetes mellitus and tuberculosis in Saudi Arabia. The literature between 1990 to 2007 was 
reviewed and combined with personal views which are supported by scientific evidences.  
Results 
Diabetes mellitus is a risk factor to develop active tuberculosis with odd ratio (4.7; 95%) 
confidence interval (2.7-8.1). The odd ratio of patients with active tuberculosis who has type 2 
diabetes mellitus ranges from 1.3-7.8 folds. Patients with tuberculosis who have diabetes 
mellitus present a higher bacillary load in sputum, more frequently positive culture at tow 
month after anti-tuberculous treatment and high rates of multi-drug resistant mycobacterium. 
Pulmonary tuberculosis in diabetes mellitus present with atypical radiographic features. 
Diabetes mellitus may adversely affect the outcome of tuberculosis treatment.  
Conclusion and Recommendations 
There is a need to alert all physicians about the potential impact of diabetes mellitus on the 
control of tuberculosis and its treatment. It is important to check fasting blood sugar in new 
patients with tuberculosis and to screen all patients with diabetes mellitus for latent 
mycobacterium tuberculosis infection. Patients with combined diabetes mellitus and 
tuberculosis require close monitoring for the control of both diseases.  
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between DM and TB  is re-emerging because 
the epidemiology of both diseases is 
progressive worldwide and cases of DM are 
increasing in the developing countries 
where TB is of high burden.  The association 
of DM with TB was confirmed with Odd 
Ratio: (OR 4.7; 95 % CI, 2.7-8.1 ) 4. Host 
defense against mycobacterium tuberculosis 
(M.TB) infection is largely mediated by 
cellular immune responses. Type-1 helper 
(Th1) cells play a central role in the host 
defense by inducing the production of 
interferon (IFN-Ǆ) which potentiates the 
nitric oxide (NO)-dependant killing activity 
of macrophages 5 . Interleukin(IL)-12 is 
essential cytokine for the development of  
Th1 cells from naïve cells 6 .   
The mechanism for the increased 
susceptibility of patients with DM to TB is 
still unclear and remains to be fully 
understood. In clinical investigations Th1 
cells and the production of IFN-Ǆ and IL-12 
were demonstrated to be attenuated in TB 
patients with DM when compared to non-
diabetic cases. The reduced Th1 responses 
correlated well with the progression of the 
diabetic conditions 7 .   
The consequence of this combination is 
substantial but it was largely marginal in the 
late century probably due to the following 
explanations:  
1) Improved health care facilities including 
diagnosis and management of both diseases 
which are on the contrariety overriding the 
primary preventive care in the developing 
communities. 2) Diminution of TB control 
measures to prevent re-activation of latent 
M.tuberculosis infection in specific group of 
patients including diabetics. 3) Lack of 
major epidemiological surveys which 
determine the prevalence of TB in diabetic 
patients. 4) Increased awareness about DM 
as a major risk factor for coronary artery 
diseases (CAD), cerebrovascular diseases, 
renal diseases, and neuropathies yet the 
awareness of the infectious diseases 
complications as an immunosuppressive 
condition. In Saudi Arabia, there is neither a 
national surveillance of cases of active TB 
among patients with diabetes mellitus nor 
surveillance of latent TB among this group 
of patients.  
The aim of this perspective is to provide an 
overview, understanding and future 
prediction of the prevalent concomitant DM 
and TB in Saudi Arabia.  The English 
literature between 1990 and 2007 was 
reviewed and combined with expert opinion 
and views which are supported by scientific 
evidences. 
 
Epidemiology 
 
Eight of the ten countries with the highest 
incidence of DM worldwide are also 
classified as high burden countries for TB by 
the World Health Organization (WHO) 8,9 . 
As a result, a growing number of patients 
with TB will present with DM and almost 
10%-30% patients with TB may have DM 4,9 . 
Type 2 DM (NIDDM) increases the risk of 
developing active TB. The odd ratio (OR) of 
patients with active TB who has type 2 DM 
ranges from 1.3-7.8 folds, indicating that 
DM clearly increases the risk of tuberculosis 
10,11 . There was a 26- and 7-fold risk of 
developing TB among IDDM (type 1 DM) 
IDDM and NIDDM patients respectively 12. 
Comparing the incidence of pulmonary TB 
in diabetics and non diabetics the relative 
risk (RR) of developing pulmonary TB and 
bacteriologically confirmed cases were 3.47 
times and 5.15 times higher 13. The 
prevalence of TB in diabetic patients was 10 
times higher than in non-diabetic patients in 
Pakistan 14.   
In Saudi Arabia, the overall prevalence of 
DM obtained by a major national survey 
over 5 years period in Saudi subjects in the 
age group 30-70 years between 1995 and 
2000 was 23.7%15. DM prevalence was 
consistently increasing with advanced age 15-
19. Studies showed that diabetes is epidemic 
in the country with exceedingly high rates 
concentrated in urban areas with significant 
different geographical distribution. The 
highest prevalence of DM was observed in 
the northern region of 27.9% followed by the 
eastern region of 26.4% then from western 
region 24.7% and from the central region of 
23.7% whereas the southern region had the 
lowest prevalence of 18.2%  15-19.  
Although the western region is mainly an 
urban community, there were foci of high 
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prevalence of latent M.tuberculosis infection 
as evident by a positive Tuberculin Skin Test 
(TST) reaction in 20% 20. This problem may 
be caused by the fact that the province 
receives every year over a million pilgrims.  
Based on our knowledge about the life time 
risk of developing active TB from latent TB 
infection in normal individuals which is 
reaching up to 20% 21, we are facing 
potential dual risk of TB re-activation in this 
country which is not only the growing 
nature of population with advanced age but 
also the concomitant underlying DM in the 
growing young individuals. These strong 
epidemiological associations provide 
important alert for physicians about the 
potential impact of DM on the control, 
eradication and treatment of TB. 
 
Clinical presentation of combined TB 
and DM  
 
Both diseases may impact adversely on each 
other with a resultant poor glycemic control 
of DM and poor response to anti-TB 
treatment. DM may not be discovered at 
time of TB diagnosis. Half of the diabetic 
patients were unaware about DM at the time 
of the national survey in Saudis 15. One-third 
of  non-diabetic men with TB had abnormal 
glucose screening tests 22 . Active TB may 
worsen blood sugar control with increase 
risk to develop sepsis in diabetic patients 21. 
Recently, in a major prospective clinical 
trial, patients with DM  and TB  found to 
have more symptoms than non-diabetic 
patients 23 .  
The correlation between the prevalence of 
TB and the duration of diabetes is variable 
15, 24 . The mean age was 55.4 years (SD +/- 
13.5) in majority of patients with 
concomitant disease 24 . Pulmonary TB in 
DM frequently present with atypical 
radiographic features compared to upper 
lobe cavitations in non-diabetic patients 23. 
The lower lung field was most frequently 
involved followed by the upper and middle 
lobe. Bilateral involvement, an associated  
pleural effusion, and cavitations were seen 
in about 50% 33% , 30 % respectively 15. 
Radiological findings included fibrosis, 
consolidation, homo- and heterogenous 
opacities 24 .  
There are data indicating that patients with  
DM who have TB present a higher bacillary 
load in sputum. Sputum microscopic 
examination results are more frequently 
positive among diabetic patients and 
associated with positive culture for M. 
tuberculosis tow months after starting the 
anti-TB treatment 23,25-27. Higher rates of 
Multi-drug resistant (MDR) M.tuberculosis 
may be associated with treatment failure in 
patients with DM  and TB concomitant 
disease.  
In certain population MDR is more frequent 
among patients with TB and DM, yet the 
mechanism is unknown 28.  Rifampicin 
pharmacokinetics indicated that plasma 
levels of the drug were 2 folds lower in 
patients with TB who have DM than in 
patients with TB who do not have DM. The 
difference may be the underlying cause to 
acquire drug resistance and may explain the 
lower mycobacterium response to anti-TB 
treatment in diabetic patients. However, 
non-compliance or non-adherence to 
treatment may lead to treatment failure 27-30 .  
  
Role of prevention of TB reactivation 
in the diabetics 
 
Physicians treating DM have only a little 
concern on TB. Probably because there are 
no longitudinal epidemiological studies 
about TB in diabetics and non -diabetics in 
Saudi Arabia and no cross sectional studies 
about the prevalence of TB in this high risk 
group of patients. There were only few 
observational studies about pulmonary , 
miliary and extrapulmonary TB in which 
DM  was the most common underlying 
disease associated 31,32 .  
Early effective interventions in high risk 
groups will reduce the burden of cavitating 
disease and associated transmission of the 
disease in the community 33. Adequate 
chemoprophylaxis substantially reduces the 
risk of TB reactivation by 70% and is 
economically cost-effective 34. The 
prevention of active TB through the 
treatment of latent TB infection is a major 
element for TB control and elimination 
strategies. Targeted treatment for persons 
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who are at high risk for reactivation TB will 
be needed to achieve this goal and could 
help to eliminate the tuberculous disease . In 
making decisions about the need to treat 
latent TB in a person with a positive TST , 
risks other than that of reactivation should 
not be considered since these risks cannot be 
decreased by the treatment of latent TB 21  .  
Chemoprophylaxis is recommended and 
considered to prevent the development of 
TB from diabetics in whom chest X-ray 
examination shows healing of TB (no signs 
of active TB) in the absence of previous 
history of TB treatment 34. Isoniazid 
prophylaxis should preferably be set 35. As 
diabetics are considered high risk group of 
developing pulmonary TB as compromised 
hosts, physicians need to perform periodic 
health exam including CXR and when the 
patient has symptomatology   to proceed 
with sputum for AFB and had a tight blood 
sugar monitoring and control of 
hyperglycemia in these patients 33-35. As 
shown by various experimental studies, the 
control of hyperglycemia improves the 
impaired Th1 related cytokine synthesis 
with improvement of the impaired host 
protection against the infection 7 . 
 
Future Predication 
 
The epidemiology of DM and TB is 
progressing and the impact of this 
convergence is serious in the control of TB.  
There are many questions to be answered: 
what are the magnitude and impact of the 
combination of DM with TB locally, 
regionally and internationally ? should 
every patient with DM be screened for latent 
TB infection and if the results are positive 
what is the level of evidence to receive INH 
prophylaxis to prevent development of 
active diseases? Is there a need to modify 
the anti-TB treatment in patients with TB 
and DM? However, on the basis of the 
current available knowledge and evidence it 
would be a wise approach to check fasting 
blood sugar in new patients with TB whom 
will be monitored closely with special 
attention for potential treatment failure 36. 
In the author’s opinion, there is a national 
requirement to start a community – based 
epidemiological health survey of TB, in 
diabetic patients to determine the 
prevalence of TB among Saudis with DM.  
Public health education and awareness 
programs should be encouraged. Such 
programs must include the importance of 
screening all TB patients for DM and 
screening all DM patients for TB using the 
new WHO criteria to diagnose both diseases 
37-39.  
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